Aclaris Capex To Depreciation from 2010 to 2025
| ACRS Stock | USD 1.83 0.01 0.55% |
Capex To Depreciation | First Reported 2010-12-31 | Previous Quarter 0.14993804 | Current Value 0.14 | Quarterly Volatility 16.04834728 |
Check Aclaris Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aclaris Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 766.6 K, Interest Expense of 3.2 M or Selling General Administrative of 21.5 M, as well as many indicators such as Price To Sales Ratio of 9.73, Dividend Yield of 0.0 or PTB Ratio of 0.7. Aclaris financial statements analysis is a perfect complement when working with Aclaris Therapeutics Valuation or Volatility modules.
Aclaris | Capex To Depreciation |
Latest Aclaris Therapeutics' Capex To Depreciation Growth Pattern
Below is the plot of the Capex To Depreciation of Aclaris Therapeutics over the last few years. It is the ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets. Aclaris Therapeutics' Capex To Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aclaris Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Capex To Depreciation | 10 Years Trend |
|
Capex To Depreciation |
| Timeline |
Aclaris Capex To Depreciation Regression Statistics
| Arithmetic Mean | 11.79 | |
| Geometric Mean | 2.35 | |
| Coefficient Of Variation | 136.14 | |
| Mean Deviation | 14.35 | |
| Median | 1.93 | |
| Standard Deviation | 16.05 | |
| Sample Variance | 257.55 | |
| Range | 34.61 | |
| R-Value | (0.84) | |
| Mean Square Error | 83.30 | |
| R-Squared | 0.70 | |
| Significance | 0.000056 | |
| Slope | (2.82) | |
| Total Sum of Squares | 3,863 |
Aclaris Capex To Depreciation History
About Aclaris Therapeutics Financial Statements
Aclaris Therapeutics shareholders use historical fundamental indicators, such as Capex To Depreciation, to determine how well the company is positioned to perform in the future. Although Aclaris Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aclaris Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aclaris Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capex To Depreciation | 0.15 | 0.14 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.